Vericel Corp (VCEL) stock
VCELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 15/30240% above fair value
$56.96−0.46 (-0.80%)
Close on Nov 13, 2026Market cap $2.92BP/E 96.5Yield –
Vericel enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Vericel's enterprise value was $2.88B on Nov 11, 2026, against $1.90B a year earlier. Over the last 5 years it ranged from $966.66M to $2.88B, with a median of $1.68B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $2.88B | +70.9% |
| 2025 | Dec 31, 2025 | $1.68B | -35.3% |
| 2024 | Dec 31, 2024 | $2.60B | +63.5% |
| 2023 | Dec 29, 2023 | $1.59B | +40.7% |
| 2022 | Dec 30, 2022 | $1.13B | -34.9% |
| 2021 | Dec 31, 2021 | $1.74B | +32.4% |
| 2020 | Dec 31, 2020 | $1.31B | +87.7% |
| 2019 | Dec 31, 2019 | $699.99M | +5.0% |
| 2018 | Dec 31, 2018 | $666.59M | +266.5% |
| 2017 | Dec 29, 2017 | $181.88M | +190.9% |
| 2016 | Dec 30, 2016 | $62.52M | +46.3% |
| 2015 | Dec 31, 2015 | $42.72M | +22.5% |
| 2014 | Dec 31, 2014 | $34.88M | +1005.8% |
| 2013 | Dec 31, 2013 | $3.15M | -90.8% |
| 2012 | Dec 31, 2012 | $34.13M | +10.5% |
| 2011 | Dec 30, 2011 | $30.89M | -37.2% |
| 2010 | Dec 31, 2010 | $49.19M | +79.9% |
| 2009 | Dec 31, 2009 | $27.33M | – |
See a number that looks wrong?